News & Events - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Home - Organovo, Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases Read More »
Pipeline - Organovo, Inc.
Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science. In addition to FXR314, Organovo is planning to begin medicinal chemistry in 2023 to create a novel drug for another, as yet undisclosed, target.
Organovo Highlights FXR314 Combination Therapy Potential and …
Nov 8, 2023 · In both Organovo’s proprietary 3D human models and in preclinical animal models of disease, FXR314 treatment demonstrates a reduction in the disruption of the intestinal lining, which protects against bacteria penetrating into the intestinal wall.
Media Coverage - Organovo, Inc.
Merck 'bio-inks' deal to use Organovo's 3D printed liver for preclinical studies
About - Organovo, Inc.
© 2025 Organovo Holdings Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121
Norman Staskey - Organovo, Inc.
Corporate Headquarters. 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121 Tel: (858) 224-1000
Who We Are - Organovo, Inc.
Organovo creates human models of inflammatory bowel disease (IBD) using our 3D tissue technologies and uses them to understand, invent, and develop the best drug therapies for ulcerative colitis and Crohn’s disease.
3D bioprinted therapeutic liver tissue - Organovo, Inc.
The critical shortage of donor organs creates an urgent need for novel treatments for patients with inborn errors of metabolism and end stage liver failure. Conventional cell therapy and tissue engineering approaches for treating liver diseases and injury are limited by low cell retention, poor engraftment, poor graft durability, and complications including portal hypertension. Integration […]
Organovo Announces Appointment of Norman Staskey as Chief …
4 days ago · SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.